| Name | Title | Contact Details |
|---|
A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, revenues reached €1.965 billion with 90% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
G-CON Manufacturing, Inc.`s prefabricated, turnkey cleanroom systems represent a significant transition to forward thinking in pharmaceutical and biopharmaceutical processing. G-CON Manufacturing, the innovator of autonomous cleanroom PODs, turned the challenges experienced by the biopharmaceutical industry into readily deployable, flexible, mobile and scalable cleanroom solutions. PODs are ideal for multi-product sites, rigorous containment needs, and on demand scaling of production and laboratory space. Building on its first design in 2009, G-CON now has a wide array of cleanroom PODs in their product portfolio to accommodate the increased demand from the pharmaceutical, biopharmaceutical and cell therapeutic industries. Moreover, G-CON`s patent portfolio continues to grow which will effectively preclude imitators from copying G-CON`s initial and more recent innovations. At G-CON, we will continue to evolve and grow with the industry to provide a comprehensive cleanroom solution that truly is flexible, scalable and fast, all for a fair and known price from the time the contract is signed.
Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.
Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity`s greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio`s technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.
CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.